STOCK TITAN

[Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Michael R. McMullen, a director of Bristol-Myers Squibb Company (BMY), reported an acquisition on 09/30/2025 of 776.053 Deferred Share Units. Each Deferred Share Unit will convert into one share of common stock upon settlement, and the units become settleable when the reporting person ceases to be a director or at a previously specified future date. Following this transaction and prior deferred holdings, the filing shows the reporting person beneficially owns 10,076.278 shares (direct). The Form 4 was filed by an attorney-in-fact and signed on behalf of Mr. McMullen on 10/02/2025.

Michael R. McMullen, direttore di Bristol-Myers Squibb Company (BMY), ha comunicato un'acquisizione il 09/30/2025 di 776.053 Unità Azionarie Differite. Ogni Unità Azionaria Differita si convertirà in una azione ordinaria al momento del regolamento, e le unità diventano regolabili quando la persona che riporta il dato cessa di essere direttore o alla data futura prestabilita. A seguito di questa operazione e delle posizioni differite precedenti, la dichiarazione mostra che la persona che riferisce detiene beneficamente 10.076.278 azioni (dirette). Il Modulo 4 è stato presentato da un procuratore-in-fatto e firmato per conto del signor McMullen il 02/10/2025.

Michael R. McMullen, director de Bristol-Myers Squibb Company (BMY), informó una adquisición el 09/30/2025 de 776.053 Unidades Diferidas de Acciones. Cada Unidad Diferida de Acciones se convertirá en una acción común al momento de su liquidación, y las unidades se vuelven liquidables cuando la persona que informa deja de ser director o en la fecha futura previamente especificada. Tras esta transacción y las tenencias diferidas anteriores, el expediente muestra que la persona que reporta posee beneficamente 10.076.278 acciones (directas). El Formulario 4 fue presentado por un mandatario y firmado en nombre del Sr. McMullen el 02/10/2025.

Michael R. McMullen, Bristol-Myers Squibb Company (BMY)의 이사로서 2025년 9월 30일776.053 연기주 단위를 취득했다고 보고했습니다. 각 연기주 단위는 정산 시 보통주 1주로 전환되며, 이 단위는 보고자가 이사가 그만두거나 미리 지정된 향후 날짜에 결제 가능해집니다. 이 거래와 이전의 연기 보유 내역을 고려하면, 보고자는 10,076.278주를 직접적으로 보유하고 있는 것으로 보고됩니다. 양식 4은 대리인에 의해 제출되었고 McMullen 씨를 대신해 2025년 10월 2일에 서명되었습니다.

Michael R. McMullen, administrateur de Bristol-Myers Squibb Company (BMY), a signalé une acquisition le 30/09/2025 de 776.053 Unités d’Actions Différées. Chaque Unité d’Actions Différées se convertira en une action ordinaire lors du dénouement, et les unités deviennent négociables lorsque la personne qui déclare les informations cesse d’être administrateur ou à la date future préalablement spécifiée. Après cette transaction et les positions différées antérieures, le dépôt indique que la personne déclarant détient bénéficiairement 10.076.278 actions (directes). Le Formulaire 4 a été déposé par un mandataire et signé au nom de M. McMullen le 02/10/2025.

Michael R. McMullen, Direktor bei Bristol-Myers Squibb Company (BMY), meldete am 30.09.2025 den Erwerb von 776.053 Deferred Share Units. Jede Deferred Share Unit wird bei Abwicklung in eine Stammaktie umgewandelt, und die Einheiten werden teilbar, wenn die meldepflichtige Person kein Direktor mehr ist oder am vorher festgelegten zukünftigen Datum. Nach dieser Transaktion und bestehenden vorherigen def. Beständen zeigt die Anmeldung, dass die meldepflichtige Person direkt 10.076.278 Aktien besitzt. Das Form 4 wurde von einem Bevollmächtigten eingereicht und im Namen von Herrn McMullen am 02.10.2025 unterzeichnet.

Michael R. McMullen، مدير في شركة بريستول-مايرز سكويب (BMY)، أفاد بعملية استحواذ في 30/09/2025 على 776.053 وحدة أسهم مؤجلة. كل وحدة أسهم مؤجلة ستتحول إلى سهم عادي عند التسوية، وتصبح الوحدات قابلة للتسوية عندما يتوقف الشخص المبلغ عن كونه مديراً أو عند التاريخ المستقبلي المحدد سلفاً. وبعد هذه المعاملة ووجود الحيازات المؤجلة السابقة، تُظهر الإيداع أن الشخص المبلغ يمتلك بنعمة 10.076.278 سهماً (مباشر). تم تقديم النموذج 4 بواسطة وكيل مفوض وموقع نيابة عن السيد McMullen في 02/10/2025.

Michael R. McMullen,为 Bristol-Myers Squibb Company (BMY) 的董事,已在 2025/09/30 报告取得 776.053 延迟股份单位。每单位延迟股将在清算时转换为一股普通股,且当报告人不再担任董事或在先前指定的未来日期时,这些单位可结算。在此次交易及此前的延期持有之后,申报显示报告人直接拥有 10.076.278 股。Form 4 由一人代理签署并于 2025/10/02 代表McMullen先生签署。

Positive
  • Acquired 776.053 Deferred Share Units on 09/30/2025
  • Beneficial ownership increased to 10,076.278 shares (direct)
Negative
  • None.

Michael R. McMullen, direttore di Bristol-Myers Squibb Company (BMY), ha comunicato un'acquisizione il 09/30/2025 di 776.053 Unità Azionarie Differite. Ogni Unità Azionaria Differita si convertirà in una azione ordinaria al momento del regolamento, e le unità diventano regolabili quando la persona che riporta il dato cessa di essere direttore o alla data futura prestabilita. A seguito di questa operazione e delle posizioni differite precedenti, la dichiarazione mostra che la persona che riferisce detiene beneficamente 10.076.278 azioni (dirette). Il Modulo 4 è stato presentato da un procuratore-in-fatto e firmato per conto del signor McMullen il 02/10/2025.

Michael R. McMullen, director de Bristol-Myers Squibb Company (BMY), informó una adquisición el 09/30/2025 de 776.053 Unidades Diferidas de Acciones. Cada Unidad Diferida de Acciones se convertirá en una acción común al momento de su liquidación, y las unidades se vuelven liquidables cuando la persona que informa deja de ser director o en la fecha futura previamente especificada. Tras esta transacción y las tenencias diferidas anteriores, el expediente muestra que la persona que reporta posee beneficamente 10.076.278 acciones (directas). El Formulario 4 fue presentado por un mandatario y firmado en nombre del Sr. McMullen el 02/10/2025.

Michael R. McMullen, Bristol-Myers Squibb Company (BMY)의 이사로서 2025년 9월 30일776.053 연기주 단위를 취득했다고 보고했습니다. 각 연기주 단위는 정산 시 보통주 1주로 전환되며, 이 단위는 보고자가 이사가 그만두거나 미리 지정된 향후 날짜에 결제 가능해집니다. 이 거래와 이전의 연기 보유 내역을 고려하면, 보고자는 10,076.278주를 직접적으로 보유하고 있는 것으로 보고됩니다. 양식 4은 대리인에 의해 제출되었고 McMullen 씨를 대신해 2025년 10월 2일에 서명되었습니다.

Michael R. McMullen, administrateur de Bristol-Myers Squibb Company (BMY), a signalé une acquisition le 30/09/2025 de 776.053 Unités d’Actions Différées. Chaque Unité d’Actions Différées se convertira en une action ordinaire lors du dénouement, et les unités deviennent négociables lorsque la personne qui déclare les informations cesse d’être administrateur ou à la date future préalablement spécifiée. Après cette transaction et les positions différées antérieures, le dépôt indique que la personne déclarant détient bénéficiairement 10.076.278 actions (directes). Le Formulaire 4 a été déposé par un mandataire et signé au nom de M. McMullen le 02/10/2025.

Michael R. McMullen, Direktor bei Bristol-Myers Squibb Company (BMY), meldete am 30.09.2025 den Erwerb von 776.053 Deferred Share Units. Jede Deferred Share Unit wird bei Abwicklung in eine Stammaktie umgewandelt, und die Einheiten werden teilbar, wenn die meldepflichtige Person kein Direktor mehr ist oder am vorher festgelegten zukünftigen Datum. Nach dieser Transaktion und bestehenden vorherigen def. Beständen zeigt die Anmeldung, dass die meldepflichtige Person direkt 10.076.278 Aktien besitzt. Das Form 4 wurde von einem Bevollmächtigten eingereicht und im Namen von Herrn McMullen am 02.10.2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
McMullen Michael R.

(Last) (First) (Middle)
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 AND PROVINCE LINE ROAD

(Street)
PRINCETON NJ 08543

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Share Units (1) 09/30/2025 A 776.053 (1) (1) Common Stock, $0.10 par value 776.053 $0 10,076.278(2) D
Explanation of Responses:
1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Remarks:
/s/ Sophie M. Bail, attorney-in-fact for Michael R. McMullen 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael R. McMullen report on the BMY Form 4?

He reported acquiring 776.053 Deferred Share Units on 09/30/2025, which convert to common shares upon settlement.

How many Bristol-Myers Squibb shares does McMullen beneficially own after the transaction?

The Form 4 reports 10,076.278 shares beneficially owned following the reported transaction(s).

When do the Deferred Share Units become settleable?

According to the filing, the Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Was a price reported for the Deferred Share Units on the Form 4?

No purchase price is reported for the Deferred Share Units; the filing shows a $0 price for the units.

Who signed the Form 4 for Michael R. McMullen and when?

The Form was signed by Sophie M. Bail, attorney-in-fact for Michael R. McMullen, on 10/02/2025.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

96.54B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON